Richard Neubig

List of Publications by Year in Descending Order

258 papers	11,433 citations	56 h-index	96 g-index
416 ext. papers	12,367 ext. citations	5.6 avg, IF	6.13 L-index

#	Paper	IF	Citations
258	BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors.. *Frontiers in Oncology*, **2022**, 12, 766794	5.3	
257	COVID-19-A Theory of Autoimmunity Against ACE-2 Explained. *Frontiers in Immunology*, **2021**, 12, 582166	8.4	20
256	Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in -Mutant Melanoma Cell Lines. *Cancers*, **2021**, 13,	6.6	1
255	Transforming Growth Factor 1 Increases Expression of Contractile Genes in Human Pulmonary Arterial Smooth Muscle Cells by Potentiating Sphingosine-1-Phosphate Signaling. *Molecular Pharmacology*, **2021**, 100, 53-60	4.3	1
254	Mice with an RGS-insensitive G protein show growth hormone axis dysfunction. *Molecular and Cellular Endocrinology*, **2021**, 521, 111098	4.4	1
253	Convergent olfactory trace amine-associated receptors detect biogenic polyamines with distinct motifs via a conserved binding site. *Journal of Biological Chemistry*, **2021**, 297, 101268	5.4	3
252	Two highly related odorant receptors specifically detect bile acid pheromones in sea lamprey (). *Journal of Biological Chemistry*, **2020**, 295, 12153-12166	5.4	3
251	Mice with R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 373, 24-33	4.7	8
250	Class A Orphans (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. *IUPHAR/BPS Guide To Pharmacology CITE*, **2020**, 2020,	1.7	2
249	Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells. *Oncogene*, **2020**, 39, 1466-1483	9.2	16
248	Mouse models of GNAO1-associated movement disorder: Allele- and sex-specific differences in phenotypes. *PLoS ONE*, **2019**, 14, e0211066	3.7	8
247	The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in Kras; Pdx1-Cre (KC) mice. *Scientific Reports*, **2019**, 9, 7072	4.9	10
246	Cover Image, Volume 87, Issue 2. *Proteins: Structure, Function and Bioinformatics*, **2019**, 87, C1-C1	4.2	
245	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. *ACS Pharmacology and Translational Science*, **2019**, 2, 92-100	5.9	12
244	Introduction to Cellular Signal Transduction **2019**, 1-19		
243	Mechanisms of Cellular Signal Transduction **2019**, 21-48		
242	5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. *Journal of Medicinal Chemistry*, **2019** , 62, 4350-4369	8.3	21

241	A Two-Pulse Cellular Stimulation Test Elucidates Variability and Mechanisms in Signaling Pathways. *Biophysical Journal*, **2019**, 116, 962-973	2.9	7
240	Spermine in semen of male sea lamprey acts as a sex pheromone. *PLoS Biology*, **2019**, 17, e3000332	9.7	19
239	Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay. *Scientific Reports*, **2019**, 9, 10278	4.9	2
238	RAC1 Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. *Cancer Cell*, **2019**, 36, 68-83.e9	24.3	43
237	Class A Orphans (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database. *IUPHAR/BPS Guide To Pharmacology CITE*, **2019**, 2019,	1.7	5
236	A Salt Bridge between α4 and α5 Helices Drives Differences in Flexibility and Potency of Inhibition among Regulator of G-protein Signaling (RGS) Proteins. *FASEB Journal*, **2019**, 33, 784.16	0.9	
235	Mice with Gnao1 G203R Gain-of-Function (GOF) Mutation Phenocopy Combined Movement Disorder and Seizures of Patients. *FASEB Journal*, **2019**, 33, 667.4	0.9	
234	An Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency for Regulators of G-protein Signaling Proteins 4, 8, and 19. *Molecular Pharmacology*, **2019**, 96, 683-691	4.3	4
233	Loss-of-Function Mutations in Human Regulator of G Protein Signaling RGS2 Differentially Regulate Pharmacological Reactivity of Resistance Vasculature. *Molecular Pharmacology*, **2019**, 96, 826-834	4.3	5
232	Interplay of cysteine exposure and global protein dynamics in small-molecule recognition by a regulator of G-protein signaling protein. *Proteins: Structure, Function and Bioinformatics*, **2019**, 87, 146-156	4.2	9
231	Differential Protein Dynamics of Regulators of G-Protein Signaling: Role in Specificity of Small-Molecule Inhibitors. *Journal of the American Chemical Society*, **2018**, 140, 3454-3460	16.4	19
230	Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80. *British Journal of Pharmacology*, **2018**, 175, 891-901	8.6	24
229	Novel antifibrotic target related to RhoA-induced MRTF activation in fibrotic diseases. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, SY84-4	0	
228	Loss of function RGS2 mutations augment vascular contractility ex vivo. *FASEB Journal*, **2018**, 32, 699.2	0.9	
227	Role of Protein Dynamics in Selectivity of Thiadiazolidinone Inhibition of RGS Proteins. *FASEB Journal*, **2018**, 32, 557.9	0.9	
226	In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis. *Journal of Nanobiotechnology*, **2018**, 16, 97	9.4	11
225	Role of hippocampal 5-HT1A receptors in the antidepressant-like phenotype of mice expressing RGS-insensitive Gi2 protein. *Neuropharmacology*, **2018**, 141, 296-304	5.5	2
224	Interpreting Hydrogen-Deuterium Exchange Events in Proteins Using Atomistic Simulations: Case Studies on Regulators of G-Protein Signaling Proteins. *Journal of Physical Chemistry B*, **2018**, 122, 9314-9323	3.4	19

223	A mechanistic review on GNAO1-associated movement disorder. *Neurobiology of Disease*, **2018**, 116, 131-141	7.5	29
222	Chemerin-induced arterial contraction is G- and calcium-dependent. *Vascular Pharmacology*, **2017**, 88, 30-41	5.9	25
221	Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 1744-1749	2.9	26
220	Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis. *Scientific Reports*, **2017**, 7, 518	4.9	41
219	The DRY motif and the four corners of the cubic ternary complex model. *Cellular Signalling*, **2017**, 35, 16-23	4.9	10
218	Regulator of G Protein Signaling 6 Protects the Heart from Ischemic Injury. *Journal of Pharmacology and Experimental Therapeutics*, **2017**, 360, 409-416	4.7	10
217	Human Missense Mutations in Regulator of G Protein Signaling 2 Affect the Protein Function Through Multiple Mechanisms. *Molecular Pharmacology*, **2017**, 92, 451-458	4.3	9
216	Movement disorder in encephalopathy associated with gain-of-function mutations. *Neurology*, **2017**, 89, 762-770	6.5	45
215	The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors. *Psychopharmacology*, **2017**, 234, 29-39	4.7	16
214	Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma. *Molecular Cancer Therapeutics*, **2017**, 16, 193-204	6.1	24
213	A central role for R7bp in the regulation of itch sensation. *Pain*, **2017**, 158, 931-944	8	7
212	Investigating Regulator of G-protein Signaling (RGS) Protein Dynamics by Hydrogen/Deuterium Exchange. *FASEB Journal*, **2017**, 31, 665.8	0.9	
211	Optimisation of Intestinal Fibrosis and Survival in the Mouse S. Typhimurium Model for Anti-fibrotic Drug Discovery and Preclinical Applications. *Journal of Crohn's and Colitis*, **2017**, 11, 724-736	1.5	4
210	RGS Proteins and GP2 Modulate Sleep, Wakefulness, and Disruption of Sleep/ Wake States after Isoflurane and Sevoflurane Anesthesia. *Sleep*, **2016**, 39, 393-404	1.1	5
209	Digoxin-Mediated Upregulation of RGS2 Protein Protects against Cardiac Injury. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 357, 311-9	4.7	13
208	Small-Molecule Inhibition of Rho/MKL/SRF Transcription in Prostate Cancer Cells: Modulation of Cell Cycle, ER Stress, and Metastasis Gene Networks. *Microarrays (Basel, Switzerland)*, **2016**, 5,		11
207	Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis. *American Journal of Pathology*, **2015**, 185, 969-86	5.8	108
206	Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors. *ACS Chemical Neuroscience*, **2015**, 6, 911-9	5.7	34

205	RGS-Insensitive G Proteins as In Vivo Probes of RGS Function. *Progress in Molecular Biology and Translational Science*, **2015**, 133, 13-30	4	17
204	M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. *Neuron*, **2015**, 88, 762-73	13.9	129
203	FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex. *PLoS ONE*, **2015**, 10, e0123581	3.7	15
202	Band-pass processing in a GPCR signaling pathway selects for NFAT transcription factor activation. *Integrative Biology (United Kingdom)*, **2015**, 7, 1378-86	3.7	18
201	Regulator of G Protein Signaling Protein 6 (RGS6) Protects the Heart from Ischemic Injury. *FASEB Journal*, **2015**, 29, 1026.8	0.9	
200	RGS4 Differentially Regulates Antidepressant and Locomotor Behaviors In Vivo. *FASEB Journal*, **2015**, 29, 618.11	0.9	
199	RGS2 Protein Degradation is Mediated by a Novel Cullin 4B/F-box 44 E3 Ligase Complex. *FASEB Journal*, **2015**, 29, 618.15	0.9	
198	Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 349, 480-6	4.7	80
197	Redox modification of nuclear actin by MICAL-2 regulates SRF signaling. *Cell*, **2014**, 156, 563-76	56.2	113
196	Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. *American Journal of Physiology - Cell Physiology*, **2014**, 307, C2-13	5.4	52
195	Induction of the matricellular protein CCN1 through RhoA and MRTF-A contributes to ischemic cardioprotection. *Journal of Molecular and Cellular Cardiology*, **2014**, 75, 152-61	5.8	26
194	Gain-of-function mutation in Gnao1: a murine model of epileptiform encephalopathy (EIEE17)?. *Mammalian Genome*, **2014**, 25, 202-10	3.2	29
193	International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. *Pharmacological Reviews*, **2014**, 66, 918-47	22.5	156
192	Conditional disruption of interactions between Gα_{12} and regulator of G protein signaling (RGS) proteins protects the heart from ischemic injury. *BMC Pharmacology & Toxicology*, **2014**, 15, 29	2.6	8
191	Regulation of protease-activated receptor 1 signaling by the adaptor protein complex 2 and R4 subfamily of regulator of G protein signaling proteins. *Journal of Biological Chemistry*, **2014**, 289, 1580-91	5.4	10
190	Identification of protein kinase C activation as a novel mechanism for RGS2 protein upregulation through phenotypic screening of natural product extracts. *Molecular Pharmacology*, **2014**, 86, 406-16	4.3	13
189	Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-βinduced fibrogenesis in human colonic myofibroblasts. *Inflammatory Bowel Diseases*, **2014**, 20, 154-65	4.5	119
188	Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 3826-32	2.9	48

187	Conformational dynamics of a regulator of G-protein signaling protein reveals a mechanism of allosteric inhibition by a small molecule. *ACS Chemical Biology*, **2013**, 8, 2778-84	4.9	30
186	NMR methods for detection of small molecule binding to RGS4. *Methods in Enzymology*, **2013**, 522, 133-52	2.7	5
185	Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay. *Cellular Signalling*, **2013**, 25, 2848-55	4.9	18
184	Microfluidic interrogation and mathematical modeling of multi-regime calcium signaling dynamics. *Integrative Biology (United Kingdom)*, **2013**, 5, 932-9	3.7	10
183	Regulation of G protein signaling by the 70kDa heat shock protein. *Cellular Signalling*, **2013**, 25, 389-96	4.9	6
182	Differential control of opioid antinociception to thermal stimuli in a knock-in mouse expressing regulator of G-protein signaling-insensitive Gαo protein. *Journal of Neuroscience*, **2013**, 33, 4369-77	6.6	24
181	International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. *Pharmacological Reviews*, **2013**, 65, 967-86	22.5	197
180	Detection of G protein-selective G protein-coupled receptor (GPCR) conformations in live cells. *Journal of Biological Chemistry*, **2013**, 288, 17167-78	5.4	48
179	Design and synthesis of tag-free photoprobes for the identification of the molecular target for CCG-1423, a novel inhibitor of the Rho/MKL1/SRF signaling pathway. *Beilstein Journal of Organic Chemistry*, **2013**, 9, 966-73	2.5	20
178	RGS 2 and RGS 4 Differentially Modulate G Protein Coupled Receptor Signaling in the Mouse Aorta. *FASEB Journal*, **2013**, 27, 1095.3	0.9	
177	Dynamic control of Allosteric Inhibitor Specificity for RGS4. *FASEB Journal*, **2013**, 27, 1095.11	0.9	
176	Increased Go activity in C57Bl/6J mice enhances sensitivity to a model of epilepsy. *FASEB Journal*, **2013**, 27, 660.1	0.9	
175	A newly identified complex of spinophilin and the tyrosine phosphatase, SHP-1, modulates platelet activation by regulating G protein-dependent signaling. *Blood*, **2012**, 119, 1935-45	2.2	47
174	Toll-like receptor-induced inflammatory cytokines are suppressed by gain of function or overexpression of Gα(12) protein. *Inflammation*, **2012**, 35, 1611-7	5.1	16
173	Gα12 signaling: friend or foe in cardiac injury and heart failure?. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2012**, 385, 443-53	3.4	10
172	Small Molecule Inhibitors of Regulator of G Protein Signalling (RGS) Proteins. *ACS Medicinal Chemistry Letters*, **2012**, 3, 146-150	4.3	39
171	Cardiotonic steroids stabilize regulator of G protein signaling 2 protein levels. *Molecular Pharmacology*, **2012**, 82, 500-9	4.3	20
170	MScreen: an integrated compound management and high-throughput screening data storage and analysis system. *Journal of Biomolecular Screening*, **2012**, 17, 1080-7		34

169	The loss of RGS protein-G□2) interactions results in markedly impaired mouse neutrophil trafficking to inflammatory sites. *Molecular and Cellular Biology*, **2012**, 32, 4561-71	4.8	28
168	Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension. *PLoS ONE*, **2012**, 7, e40829	3.7	36
167	Targeting degradation pathways of RGS2 using high-throughput siRNA screening. *FASEB Journal*, **2012**, 26, 838.9	0.9	
166	S1P induces CCN1 expression through RhoA/MRTF-a activation and protects cardiomyocytes against cell death. *FASEB Journal*, **2012**, 26, 1060.4	0.9	
165	Generation of G□2 G184S conditional mutant mice to study regulator of G protein signaling (RGS) proteins. *FASEB Journal*, **2012**, 26, 1114.10	0.9	
164	A nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteins. *Biochemistry*, **2011**, 50, 3181-92	3.2	49
163	RGS-insensitive G□subunits: probes of G□subtype-selective signaling and physiological functions of RGS proteins. *Methods in Molecular Biology*, **2011**, 756, 75-98	1.4	12
162	Hi-Fi transmission of periodic signals amid cell-to-cell variability. *Molecular BioSystems*, **2011**, 7, 2238-44		15
161	Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein response. *Journal of Biomolecular Screening*, **2011**, 16, 825-35		40
160	G□2)-mediated protection from ischaemic injury is modulated by endogenous RGS proteins in the mouse heart. *Cardiovascular Research*, **2011**, 91, 45-52	9.9	16
159	Glossary of terms used in biomolecular screening (IUPAC Recommendations 2011). *Pure and Applied Chemistry*, **2011**, 83, 1129-1158	2.1	8
158	Differential effects of Go and Gi2 on seizure threshold. *FASEB Journal*, **2011**, 25, 1010.2	0.9	
157	Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent. *Journal of Neurochemistry*, **2010**, 112, 1026-34	6	26
156	Mind your salts: when the inactive constituent isn□. *Molecular Pharmacology*, **2010**, 78, 558-9	4.3	13
155	Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. *Molecular Pharmacology*, **2010**, 78, 524-33	4.3	65
154	Allosteric inhibition of the regulator of G protein signaling-Galpha protein-protein interaction by CCG-4986. *Molecular Pharmacology*, **2010**, 78, 360-5	4.3	37
153	GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. *Bioinformatics*, **2010**, 26, 1804-57.2		71
152	RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 11086-91	11.5	56

151	Phase-locked signals elucidate circuit architecture of an oscillatory pathway. *PLoS Computational Biology*, **2010**, 6, e1001040	5	37
150	Regulators of G protein signaling proteins as targets for drug discovery. *Progress in Molecular Biology and Translational Science*, **2010**, 91, 81-119	4	76
149	Analyzing binding data. *Current Protocols in Neuroscience*, **2010**, Chapter 7, Unit 7.5	2.7	23
148	Thinking outside of the "RGS box": new approaches to therapeutic targeting of regulators of G protein signaling. *Molecular Pharmacology*, **2010**, 78, 550-7	4.3	63
147	Use of flow cytometric methods to quantify protein-protein interactions. *Current Protocols in Cytometry*, **2010**, Chapter 13, Unit 13.11.1-15	3.6	25
146	RGS/Gi2alpha interactions modulate platelet accumulation and thrombus formation at sites of vascular injury. *Blood*, **2010**, 116, 6092-100	2.2	49
145	Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 665-72	2.9	50
144	G□subunit coordinates with ephrin-B to balance self-renewal and differentiation in neural progenitor cells. *Stem Cells*, **2010**, 28, 1581-9	5.8	16
143	RGS7 Protein Suppression of Gao Protein-Mediated □2A-Adrenergic Receptor Inhibition of Mouse Hippocampal CA3 Epileptiform Activity. *FASEB Journal*, **2010**, 24, 587.3	0.9	
142	International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature. *Pharmacological Reviews*, **2009**, 61, 1-8	22.5	44
141	Polyplexed flow cytometry protein interaction assay: a novel high-throughput screening paradigm for RGS protein inhibitors. *Journal of Biomolecular Screening*, **2009**, 14, 610-9		36
140	Regulator of G protein signaling protein suppression of Galphao protein-mediated alpha2A adrenergic receptor inhibition of mouse hippocampal CA3 epileptiform activity. *Molecular Pharmacology*, **2009**, 75, 1222-30	4.3	24
139	High-throughput screening for small-molecule inhibitors of LARG-stimulated RhoA nucleotide binding via a novel fluorescence polarization assay. *Journal of Biomolecular Screening*, **2009**, 14, 161-72		38
138	IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. *Nucleic Acids Research*, **2009**, 37, D680-5	20.1	176
137	A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation. *Molecular Pharmacology*, **2009**, 75, 514-24	4.3	56
136	A conserved hydrophobic surface of the LARG pleckstrin homology domain is critical for RhoA activation in cells. *Cellular Signalling*, **2009**, 21, 1569-78	4.9	20
135	A covalent peptide inhibitor of RGS4 identified in a focused one-bead, one compound library screen. *BMC Pharmacology*, **2009**, 9, 9		17
134	GNAI2 and regulators of G protein signaling as a potential Noonan syndrome mechanism. *Medical Hypotheses*, **2009**, 73, 56-9	3.8	4

133	Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. *Neuropsychopharmacology*, **2009**, 34, 126-41	8.7	133
132	Isoflurane-induced changes in righting response and breathing are modulated by RGS proteins. *Anesthesia and Analgesia*, **2009**, 109, 1500-5	3.9	16
131	Functional Selectivity at Adrenergic Receptors **2009**, 107-124		
130	Microfabricated channel array electrophoresis for characterization and screening of enzymes using RGS-G protein interactions as a model system. *Analytical Chemistry*, **2008**, 80, 5225-31	7.8	17
129	And the winner is ... RGS4!. *Circulation Research*, **2008**, 103, 444-6	15.7	7
128	Assembly of high order G alpha q-effector complexes with RGS proteins. *Journal of Biological Chemistry*, **2008**, 283, 34923-34	5.4	43
127	Resistance to diet-induced obesity and improved insulin sensitivity in mice with a regulator of G protein signaling-insensitive G184S Gnai2 allele. *Diabetes*, **2008**, 57, 77-85	0.9	41
126	In vitro protein kinase activity measurement by flow cytometry. *Analytical Biochemistry*, **2008**, 383, 180-5	3.1	7
125	Novel peptide ligands of RGS4 from a focused one-bead, one-compound library. *Chemical Biology and Drug Design*, **2008**, 72, 111-9	2.9	20
124	2A adrenergic receptor mediated antiepileptic effects via G proteins. *FASEB Journal*, **2008**, 22, 729.3	0.9	
123	Genetic deletion of Regulators of G protein Signaling (RGS) protein activity enhances buprenorphine antinociception while limiting withdrawal behaviors associated with chronic administration. *FASEB Journal*, **2008**, 22, 907.7	0.9	
122	Mice lacking RGS protein activity at G2 exhibit a 5HT1A receptor-mediated antidepressant-like phenotype. *FASEB Journal*, **2008**, 22, 907.8	0.9	
121	High Throughtput Screening Using A Polyplexed Flow Cytometry Protein Interaction Assay (FCPIA) for Small Molecule Inhibitors of Regulator of G protein Signaling (RGS) Proteins. *FASEB Journal*, **2008**, 22, 907.2	0.9	
120	Capillary electrophoresis assay for G protein-coupled receptor-mediated GTPase activity. *Analytical Chemistry*, **2007**, 79, 1158-63	7.8	5
119	Phagocyte-derived catecholamines enhance acute inflammatory injury. *Nature*, **2007**, 449, 721-5	50.4	332
118	Missing links: mechanisms of protean agonism. *Molecular Pharmacology*, **2007**, 71, 1200-2	4.3	21
117	International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. *Pharmacological Reviews*, **2007**, 59, 5-13	22.5	255
116	N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells. *Molecular Pharmacology*, **2007**, 71, 1040-50	4.3	79

115	Structure of Galphaq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. *Science*, **2007**, 318, 1923-7	33.3	173
114	Endogenous RGS proteins modulate SA and AV nodal functions in isolated heart: implications for sick sinus syndrome and AV block. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 292, H2532-9	5.2	39
113	Fluorescence-based adenylyl cyclase assay adaptable to high throughput screening. *Combinatorial Chemistry and High Throughput Screening*, **2007**, 10, 289-98	1.3	5
112	CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. *Molecular Cancer Therapeutics*, **2007**, 6, 2249-60	6.1	162
111	The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. *Molecular Pharmacology*, **2007**, 71, 959-64	4.3	268
110	Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. *Molecular Pharmacology*, **2007**, 71, 169-75	4.3	114
109	Peptide ligands of Regulators of G-Protein Signaling 4 (RGS4) identified by screening of a focused one-bead, one-compound peptide library. *FASEB Journal*, **2007**, 21, A1002	0.9	1
108	Biphasic regulation of mu-opioid signaling to adenylyl cyclase by GTPase accelerating protein (GAP) activity of RGS7. *FASEB Journal*, **2007**, 21, A430	0.9	
107	Characterization and mechanistic investigation of CCG-4986, a small molecule RGS4 inhibitor. *FASEB Journal*, **2007**, 21, A431	0.9	1
106	Development of a Time Resolved FRET High-Throughput Assay to Identify Inhibitors of the RGS4/Gα Interaction. *FASEB Journal*, **2007**, 21, A431	0.9	1
105	Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects. *Circulation Research*, **2006**, 98, 659-66	15.7	80
104	Regions in the G protein gamma subunit important for interaction with receptors and effectors. *Molecular Pharmacology*, **2006**, 69, 877-87	4.3	26
103	Pleiotropic phenotype of a genomic knock-in of an RGS-insensitive G184S Gnai2 allele. *Molecular and Cellular Biology*, **2006**, 26, 6870-9	4.8	73
102	Mechanism of action and structural requirements of constrained peptide inhibitors of RGS proteins. *Chemical Biology and Drug Design*, **2006**, 67, 266-74	2.9	26
101	Targeting regulators of G protein signaling (RGS proteins) to enhance agonist specificity **2006**, 93-103		1
100	Receptor-antagonist interactions in the complexes of agouti and agouti-related protein with human melanocortin 1 and 4 receptors. *Biochemistry*, **2005**, 44, 3418-31	3.2	43
99	International Union of Pharmacology. XLVI. G protein-coupled receptor list. *Pharmacological Reviews*, **2005**, 57, 279-88	22.5	401
98	International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. *Pharmacological Reviews*, **2005**, 57, 541-6	22.5	191

97	Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. *Journal of Biological Chemistry*, **2005**, 280, 22564-71	5.4	44
96	Real-time detection of basal and stimulated G protein GTPase activity using fluorescent GTP analogues. *Journal of Biological Chemistry*, **2005**, 280, 7712-9	5.4	34
95	Regulators of G protein signaling & drugs of abuse. *Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics*, **2005**, 5, 30-41		81
94	Structure-based design, synthesis, and pharmacologic evaluation of peptide RGS4 inhibitors. *Chemical Biology and Drug Design*, **2004**, 63, 141-6		27
93	RGS-insensitive G-protein mutations to study the role of endogenous RGS proteins. *Methods in Enzymology*, **2004**, 389, 229-43	1.7	48
92	Ribozyme- and siRNA-mediated suppression of RGS-containing RhoGEF proteins. *Methods in Enzymology*, **2004**, 389, 244-65	1.7	10
91	Real-time analysis of ternary complex on particles: direct evidence for partial agonism at the agonist-receptor-G protein complex assembly step of signal transduction. *Journal of Biological Chemistry*, **2004**, 279, 13514-21	5.4	26
90	Endogenous regulator of G protein signaling proteins suppress Galphao-dependent, mu-opioid agonist-mediated adenylyl cyclase supersensitization. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 310, 215-22	4.7	35
89	Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. *Journal of Biological Chemistry*, **2004**, 279, 28831-4	5.4	61
88	Affinity assays using fluorescence anisotropy with capillary electrophoresis separation. *Analytical Chemistry*, **2004**, 76, 7380-6	7.8	17
87	Structure-based design, synthesis, and activity of peptide inhibitors of RGS4 GAP activity. *Methods in Enzymology*, **2004**, 389, 266-77	1.7	10
86	Diabetic neuropathy: inhibitory G protein dysfunction involves PKC-dependent phosphorylation of Goalpha. *Journal of Neurochemistry*, **2003**, 86, 1006-14	6	16
85	Ligand-receptor-G-protein molecular assemblies on beads for mechanistic studies and screening by flow cytometry. *Molecular Pharmacology*, **2003**, 64, 1227-38	4.3	35
84	International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. *Pharmacological Reviews*, **2003**, 55, 597-606	22.5	430
83	Detection of G proteins by affinity probe capillary electrophoresis using a fluorescently labeled GTP analogue. *Analytical Chemistry*, **2003**, 75, 4297-304	7.8	34
82	Depicting a protein⊖ two faces: GPCR classification by phylogenetic tree-based HMMs. *FEBS Letters* , **2003**, 554, 95-9	3.8	23
81	Inverse agonist activity of agouti and agouti-related protein. *Peptides*, **2003**, 24, 603-9	3.8	68
80	Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways. *Journal of Biological Chemistry*, **2003**, 278, 9418-25	5.4	85

79	Stimulation of cellular signaling and G protein subunit dissociation by G protein betagamma subunit-binding peptides. *Journal of Biological Chemistry*, **2003**, 278, 19634-41	5.4	61
78	A spatial focusing model for G protein signals. Regulator of G protein signaling (RGS) protien-mediated kinetic scaffolding. *Journal of Biological Chemistry*, **2003**, 278, 7278-84	5.4	107
77	Regulators of G protein signaling (RGS proteins): novel central nervous system drug targets. *Chemical Biology and Drug Design*, **2002**, 60, 312-6		34
76	Regulators of G-protein signalling as new central nervous system drug targets. *Nature Reviews Drug Discovery*, **2002**, 1, 187-97	64.1	325
75	AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. *Journal of Biological Chemistry*, **2002**, 277, 9268-77	5.4	121
74	Receptor-selective effects of endogenous RGS3 and RGS5 to regulate mitogen-activated protein kinase activation in rat vascular smooth muscle cells. *Journal of Biological Chemistry*, **2002**, 277, 24949-58	5.4	106
73	Fluorescence approaches to study G protein mechanisms. *Methods in Enzymology*, **2002**, 344, 403-20	1.7	16
72	Fluorescence analysis of receptor-G protein interactions in cell membranes. *Biochemistry*, **2002**, 41, 12858-67	3.2	25
71	NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix. *Biochemistry*, **2002**, 41, 3596-604	3.2	39
70	Mutagenesis and peptide analysis of the DRY motif in the alpha2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors. *Biochemical and Biophysical Research Communications*, **2002**, 293, 1233-41	3.4	47
69	Expression of novel splice variants of the G protein subunit, Go alpha, is tissue-specific and age-dependent in the rat. *Gene*, **2002**, 296, 249-55	3.8	4
68	Selective inactivation of guanine-nucleotide-binding regulatory protein (G-protein) alpha and betagamma subunits by urea. *Biochemical Journal*, **2001**, 354, 337-44	3.8	12
67	Selective inactivation of guanine-nucleotide-binding regulatory protein (G-protein) □and □ subunits by urea. *Biochemical Journal*, **2001**, 354, 337-344	3.8	22
66	Fluorescent BODIPY-GTP analogs: real-time measurement of nucleotide binding to G proteins. *Analytical Biochemistry*, **2001**, 291, 109-17	3.1	111
65	Molecular cloning and characterization of a novel regulator of G-protein signaling from mouse hematopoietic stem cells. *Journal of Biological Chemistry*, **2001**, 276, 915-23	5.4	45
64	Walker A lysine mutations of TAP1 and TAP2 interfere with peptide translocation but not peptide binding. *Journal of Biological Chemistry*, **2001**, 276, 7526-33	5.4	61
63	Real-time analysis of G protein-coupled receptor reconstitution in a solubilized system. *Journal of Biological Chemistry*, **2001**, 276, 22453-60	5.4	30
62	Receptor-G protein gamma specificity: gamma11 shows unique potency for A(1) adenosine and 5-HT(1A) receptors. *Biochemistry*, **2001**, 40, 10532-41	3.2	46

61	ANG II type 1 receptor downregulation does not require receptor endocytosis or G protein coupling. *American Journal of Physiology - Cell Physiology*, **2001**, 281, C801-9	5.4	16
60	Inverse agonist activity at the alpha(2A)-adrenergic receptor. *Molecular Pharmacology*, **2001**, 59, 532-42	4.3	47
59	Regulator of G protein signaling proteins: novel multifunctional drug targets. *Journal of Pharmacology and Experimental Therapeutics*, **2001**, 297, 837-45	4.7	147
58	Coupling efficacy and selectivity of the human mu-opioid receptor expressed as receptor-Galpha fusion proteins in Escherichia coli. *Journal of Neurochemistry*, **2000**, 75, 1190-9	6	26
57	Rapid kinetics of regulator of G-protein signaling (RGS)-mediated Galphai and Galphao deactivation. Galpha specificity of RGS4 AND RGS7. *Journal of Biological Chemistry*, **2000**, 275, 33497-503	5.4	78
56	Timing is everything the role of kinetics in G protein activation. *Life Sciences*, **2000**, 68, 647-58	6.8	45
55	Analysis of guanine nucleotide binding and exchange kinetics of the Escherichia coli GTPase Era. *Journal of Bacteriology*, **2000**, 182, 3460-6	3.5	34
54	Agonist-directed trafficking of porcine alpha(2A)-adrenergic receptor signaling in Chinese hamster ovary cells: l-isoproterenol selectively activates G(s). *Journal of Pharmacology and Experimental Therapeutics*, **2000**, 294, 539-47	4.7	47
53	G(i) activator region of alpha(2A)-adrenergic receptors: distinct basic residues mediate G(i) versus G(s) activation. *Molecular Pharmacology*, **1999**, 56, 1005-13	4.3	62
52	Interdomain interactions regulate GDP release from heterotrimeric G proteins. *Biochemistry*, **1999**, 38, 13795-800	3.2	37
51	Specificity of Receptor-G Protein Coupling: Protein Structure and Cellular Determinants. *Seminars in Neuroscience*, **1998**, 9, 189-197		12
50	Roles of G(o)alpha tryptophans in GTP hydrolysis, GDP release, and fluorescence signals. *Biochemistry*, **1998**, 37, 837-43	3.2	24
49	Determinants of gi1alpha and beta gamma binding. Measuring high affinity interactions in a lipid environment using flow cytometry. *Journal of Biological Chemistry*, **1998**, 273, 7934-40	5.4	65
48	A point mutation in Galphao and Galphai1 blocks interaction with regulator of G protein signaling proteins. *Journal of Biological Chemistry*, **1998**, 273, 12794-7	5.4	140
47	Cotransfection of second and third intracellular loop fragments inhibit angiotensin AT1a receptor activation of phospholipase C in HEK-293 cells. *Journal of Pharmacology and Experimental Therapeutics*, **1998**, 285, 216-22	4.7	14
46	Novel form of crosstalk between G protein and tyrosine kinase pathways. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 5417-21	11.5	85
45	Receptor and membrane interaction sites on Gbeta. A receptor-derived peptide binds to the carboxyl terminus. *Journal of Biological Chemistry*, **1996**, 271, 3336-9	5.4	81
44	Partial G protein activation by fluorescent guanine nucleotide analogs. Evidence for a triphosphate-bound but inactive state. *Journal of Biological Chemistry*, **1996**, 271, 4791-7	5.4	27

43	Structural requirements for G(o) activation by receptor-derived peptides: activation and modulation domains of the alpha 2-adrenergic receptor i3c region. *Molecular Pharmacology*, **1996**, 50, 351-8	4.3	34
42	Lack of association of G-protein beta 2- and gamma 2-subunit N-terminal fragments provides evidence against the coiled-coil model of subunit-beta gamma assembly. *Biochemical Journal*, **1995**, 309 (Pt 2), 377-80	3.8	9
41	Effect of circulating epinephrine on platelet function and hematocrit. *Hypertension*, **1995**, 25, 1096-105	8.5	31
40	Membrane organization in G-protein mechanisms. *FASEB Journal*, **1994**, 8, 939-46	0.9	326
39	Peptides as probes for G protein signal transduction. *Cellular Signalling*, **1994**, 6, 841-9	4.9	37
38	Lateral mobility of tetramethylrhodamine (TMR) labelled G protein alpha and beta gamma subunits in NG 108-15 cells. *Cellular Signalling*, **1994**, 6, 663-79	4.9	28
37	Coupling an alpha 2-adrenergic receptor peptide to G-protein: a new photolabeling agent. *Peptides*, **1994**, 15, 829-34	3.8	9
36	Rapid kinetics of G protein subunit association: a rate-limiting conformational change?. *FEBS Letters* , **1994**, 355, 251-3	3.8	21
35	Binding of an alpha 2 adrenergic receptor third intracellular loop peptide to G beta and the amino terminus of G alpha. *Journal of Biological Chemistry*, **1994**, 269, 27618-24	5.4	77
34	The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. *Journal of Pharmacology and Experimental Therapeutics*, **1994**, 271, 1558-65	4.7	80
33	Multisite interactions of receptors and G proteins: enhanced potency of dimeric receptor peptides in modifying G protein function. *Molecular Pharmacology*, **1994**, 45, 1191-7	4.3	22
32	Fluorescent guanine nucleotide analogs and G protein activation. *Journal of Biological Chemistry*, **1994**, 269, 13771-8	5.4	46
31	Binding of an alpha 2 adrenergic receptor third intracellular loop peptide to G beta and the amino terminus of G alpha.. *Journal of Biological Chemistry*, **1994**, 269, 27618-27624	5.4	81
30	Resonance energy transfer between guanine nucleotide binding protein subunits and membrane lipids. *Biochemistry*, **1993**, 32, 2409-14	3.2	12
29	Synthesis and characterization of fluorescently labeled bovine brain G protein subunits. *Biochemistry*, **1993**, 32, 2401-8	3.2	19
28	Modern NMR spectroscopy of proteins and peptides in solution and its relevance to drug design. *Journal of Computer - Aided Molecular Design*, **1993**, 1, 391-417		3
27	Compartmentation of receptors and guanine nucleotide-binding proteins in NG108-15 cells: lack of cross-talk in agonist binding among the alpha 2-adrenergic, muscarinic, and opiate receptors. *Molecular Pharmacology*, **1993**, 43, 434-43	4.3	49
26	Subsecond modulation of formyl peptide-linked guanine nucleotide-binding proteins by guanosine 5ΘO-(3-thio)triphosphate in permeabilized neutrophils. *Molecular Pharmacology*, **1993**, 43, 734-40	4.3	13

25	A threshold level of coupled G-proteins is required to transduce neutrophil responses. *Journal of Immunology*, **1992**, 149, 2172-8	5.3	13
24	Two peptides from the alpha 2A-adrenergic receptor alter receptor G protein coupling by distinct mechanisms. *Journal of Biological Chemistry*, **1991**, 266, 11025-9	5.4	70
23	Multiple Gi protein subtypes regulate a single effector mechanism. *Molecular Pharmacology*, **1991**, 40, 707-11	4.3	58
22	Subcellular distribution of alpha 2-adrenergic receptors, pertussis-toxin substrate and adenylate cyclase in human platelets. *Biochemical Journal*, **1990**, 265, 755-62	3.8	5
21	Sensitization of human alpha 1- and alpha 2-adrenergic venous responses by guanadrel sulfate. *Clinical Pharmacology and Therapeutics*, **1990**, 48, 537-43	6.1	16
20	p-[125I]iodoclonidine is a partial agonist at the alpha 2-adrenergic receptor. *Molecular Pharmacology*, **1990**, 38, 214-21	4.3	18
19	Nonadrenergic [3H]idazoxan binding sites are physically distinct from alpha 2-adrenergic receptors. *Molecular Pharmacology*, **1990**, 37, 65-8	4.3	52
18	How does a key fit a flexible lock? Structure and dynamics in receptor function. *BioEssays*, **1989**, 11, 136-41	4.1	11
17	Rapid kinetics of alpha 2-adrenergic inhibition of adenylate cyclase. Evidence for a distal rate-limiting step. *Biochemistry*, **1989**, 28, 8778-86	3.2	26
16	The hypertension-coronary heart disease dilemma: the catecholamine-blood platelet connection. *Journal of Hypertension*, **1989**, 7, 851-60	1.9	18
15	Mechanism of agonist and antagonist binding to alpha 2 adrenergic receptors: evidence for a precoupled receptor-guanine nucleotide protein complex. *Biochemistry*, **1988**, 27, 2374-84	3.2	94
14	Temperature effects on alpha 2-adrenergic receptor-Gi interactions. *Biochemical Pharmacology*, **1988**, 37, 2815-21	6	12
13	Inhibition of adenylate cyclase is mediated by the high affinity conformation of the alpha 2-adrenergic receptor. *Molecular Pharmacology*, **1988**, 34, 814-22	4.3	34
12	Membrane reconstitution of high-affinity alpha 2 adrenergic agonist binding with guanine nucleotide regulatory proteins. *Biochemistry*, **1987**, 26, 3664-72	3.2	53
11	Large-scale purification of alpha 2-adrenergic receptor-enriched membranes from human platelets. Persistent association of guanine nucleotides with nonpurified membranes. *Biochimica Et Biophysica Acta - Biomembranes*, **1986**, 854, 67-76	3.8	15
10	Guanine nucleotide effects on catecholamine secretion from digitonin-permeabilized adrenal chromaffin cells. *Journal of Biological Chemistry*, **1986**, 261, 10182-8	5.4	100
9	Guanine nucleotide effects on catecholamine secretion from digitonin-permeabilized adrenal chromaffin cells.. *Journal of Biological Chemistry*, **1986**, 261, 10182-10188	5.4	86
8	Pharmacologic reduction of sympathetic drive increases platelet alpha-2-receptor number. *Clinical Pharmacology and Therapeutics*, **1985**, 38, 519-24	6.1	21

7	Parallel inactivation of alpha 2-adrenergic agonist binding and Ni by alkaline treatment. *FEBS Letters*, **1985**, 192, 321-5	3.8	16
6	Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry. *Molecular Pharmacology*, **1985**, 28, 475-86	4.3	56
5	Conformations of Torpedo acetylcholine receptor associated with ion transport and desensitization. *Biochemistry*, **1982**, 21, 3460-7	3.2	134
4	Immunofluorescence localization at the mammalian neuromuscular junction of the Mr 43,000 protein of Torpedo postsynaptic membranes. *Proceedings of the National Academy of Sciences of the United States of America*, **1981**, 78, 5230-4	11.5	127
3	Acetylcholine and local anesthetic binding to Torpedo nicotinic postsynaptic membranes after removal of nonreceptor peptides. *Proceedings of the National Academy of Sciences of the United States of America*, **1979**, 76, 690-4	11.5	317
2	Identification of Pirin as a Molecular Target of the CCG-1423/CCG- 203971 Series of Anti-Fibrotic and Anti-Metastatic Compounds		1
1	Mice with GNAO1 R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone		1